KLRC1 and neoplasm: The results revealed a significant increase in NK cell-mediated tumor cell killing following MS-275 treatment, with NKG2A blockade by monalizumab further enhancing this effect; however, no additional benefit was observed with TIGIT blockade by tiragolumab (Fig. 4A-D).